New patent covers combining hTERT and Follistatin-344 to target telomere length, muscle mass and blood-glucose levels in age-related disease.
Link as first comment.
@longevitytech.bsky.social
Explore
@longevitytech.bsky.social
@longevitytech.bsky.socialNew patent covers combining hTERT and Follistatin-344 to target telomere length, muscle mass and blood-glucose levels in age-related disease.
Link as first comment.